Boehringer Ingelheim and Propeller Health have announced a new partnership that will allow COPD and asthma patients using Respimat inhalers “to enroll at select US health systems in a new program that is designed to determine how Propeller’s novel health technology tool for the Respimat inhaler impacts adherence rates and patient engagement.” Propeller received 510(k) clearance for use of its digital inhaler monitoring platform with the Respimat SMI in March 2015.
Propeller has also announced partnerships with GlaxoSmithKline and with Aptar Pharma in the past few months.
Boehringer Ingelheim Pharmaceuticals Executive Director and Head Ruchin Kansal commented, “As a committed partner to the respiratory community for nearly a century, Boehringer Ingelheim is proud to embark on this industry-leading partnership with Propeller with the goal of improving the care of people living with COPD and asthma.”
Propeller CEO David Van Sickle said, “We are excited to work with Boehringer Ingelheim to bring Propeller to people with asthma and COPD at health systems across the US. Together, we believe that digital tools can complement the use of respiratory medications and encourage more appropriate and effective management of chronic respiratory disease.”
Read the BI and Propeller press release.
